GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achillion Pharmaceuticals Inc (NAS:ACHN) » Definitions » Operating Margin %

Achillion Pharmaceuticals (Achillion Pharmaceuticals) Operating Margin % : 0.00% (As of Sep. 2019)


View and export this data going back to 2006. Start your Free Trial

What is Achillion Pharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Achillion Pharmaceuticals's Operating Income for the three months ended in Sep. 2019 was $-21.05 Mil. Achillion Pharmaceuticals's Revenue for the three months ended in Sep. 2019 was $0.00 Mil. Therefore, Achillion Pharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2019 was 0.00%.

The historical rank and industry rank for Achillion Pharmaceuticals's Operating Margin % or its related term are showing as below:


ACHN's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -177.195
* Ranked among companies with meaningful Operating Margin % only.

Achillion Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Achillion Pharmaceuticals's Operating Income for the three months ended in Sep. 2019 was $-21.05 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2019 was $-79.82 Mil.


Achillion Pharmaceuticals Operating Margin % Historical Data

The historical data trend for Achillion Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achillion Pharmaceuticals Operating Margin % Chart

Achillion Pharmaceuticals Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -22.85 -432.43 - -

Achillion Pharmaceuticals Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Achillion Pharmaceuticals's Operating Margin %

For the Biotechnology subindustry, Achillion Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Achillion Pharmaceuticals's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achillion Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Achillion Pharmaceuticals's Operating Margin % falls into.



Achillion Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Achillion Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2018 is calculated as

Operating Margin %=Operating Income (A: Dec. 2018 ) / Revenue (A: Dec. 2018 )
=-74.014 / 0
= %

Achillion Pharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2019 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2019 ) / Revenue (Q: Sep. 2019 )
=-21.054 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Achillion Pharmaceuticals  (NAS:ACHN) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Achillion Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of Achillion Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Achillion Pharmaceuticals (Achillion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
300 George Street, New Haven, CT, USA, 06511
Achillion Pharmaceuticals Inc is a biotechnology company that seeks to discover and commercialize treatments for rare diseases. The company is engaged solely in the discovery and development of innovative small-molecule drug therapies for infectious diseases and immune system disorders. Achillion specializes in structural biology, medicinal chemistry, and antimicrobial discovery research. The company generates revenue from product sales, regulatory and commercialization milestones, and royalties. Achillion also uses collaborative and licensing agreements.
Executives
Joseph Truitt director, officer: Chief Executive Officer C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Kurt Graves director C/O ACHILLION PHARMACEUTICALS INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Michael D Kishbauch director 18 CHERRYVILLE RD, FLEMINGTON NJ 08822
Jason S Fisherman director C/O ADVENT INTERNATIONAL CORP, 75 STATE ST 29TH FLOOR, BOSTON MA 02104
Van Nostrand Robert L director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Nicole Vitullo director 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Martha E Manning officer: General Counsel 700 PENNSYLVANIA DR, EXTON PA 19341
Frank Verwiel director C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Paul E Firuta officer: EVP, Chief Commercial Officer 550 HILLS DRIVE, THIRD FLOOR, BEDMINSTER NJ 07921
Steven Zelenkofske officer: EVP, Chief Medical Officer 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Mary Kay Fenton officer: Chief Financial Officer ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Milind Deshpande director, officer: Chief Executive Officer ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Johnson & Johnson Innovation - Jjdc, Inc. 10 percent owner 410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Johnson & Johnson 10 percent owner ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
David Apelian officer: Chief Medical Officer C/O ACHILLION PHARMACEUTICALS, INC, 300 GEORGE STREET, NEW HAVEN CT 06511

Achillion Pharmaceuticals (Achillion Pharmaceuticals) Headlines

From GuruFocus

Achillion to Present at the Barclays Global Healthcare Conference

By Marketwired Marketwired 03-08-2019